Relief Therapeutics (OTCMKTS:RLFTF) Trading Down 7.5% – What’s Next?

Relief Therapeutics Holding SA (OTCMKTS:RLFTFGet Free Report)’s share price was down 7.5% during trading on Thursday . The stock traded as low as $1.41 and last traded at $1.41. Approximately 480 shares changed hands during trading, a decline of 78% from the average daily volume of 2,147 shares. The stock had previously closed at $1.5250.

Relief Therapeutics Price Performance

The stock has a fifty day simple moving average of $2.37 and a 200-day simple moving average of $3.11.

About Relief Therapeutics

(Get Free Report)

Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.

The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.

Further Reading

Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.